pan caspase inhibitor cas Search Results


pan caspase inhibitor z vad fmk  (R&D Systems)
96
R&D Systems pan caspase inhibitor z vad fmk
Pan Caspase Inhibitor Z Vad Fmk, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor z vad fmk/product/R&D Systems
Average 96 stars, based on 1 article reviews
pan caspase inhibitor z vad fmk - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
ifnγ plus pan caspase inhibitor q vd oph  (MedChemExpress)
96
MedChemExpress ifnγ plus pan caspase inhibitor q vd oph
Ifnγ Plus Pan Caspase Inhibitor Q Vd Oph, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ifnγ plus pan caspase inhibitor q vd oph/product/MedChemExpress
Average 96 stars, based on 1 article reviews
ifnγ plus pan caspase inhibitor q vd oph - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pan-caspase inhibitor z-vad-fmk  (ApexBio)
90
ApexBio pan-caspase inhibitor z-vad-fmk
Pan Caspase Inhibitor Z Vad Fmk, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan-caspase inhibitor z-vad-fmk/product/ApexBio
Average 90 stars, based on 1 article reviews
pan-caspase inhibitor z-vad-fmk - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
inhibitors against apoptosis  (R&D Systems)
95
R&D Systems inhibitors against apoptosis
Inhibitors Against Apoptosis, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inhibitors against apoptosis/product/R&D Systems
Average 95 stars, based on 1 article reviews
inhibitors against apoptosis - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
pan-caspase inhibitor z-vad-fmk  (Cayman Chemical)
90
Cayman Chemical pan-caspase inhibitor z-vad-fmk
Pan Caspase Inhibitor Z Vad Fmk, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan-caspase inhibitor z-vad-fmk/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
pan-caspase inhibitor z-vad-fmk - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pan-caspase inhibitor q-vd-oph  (Selleck Chemicals)
90
Selleck Chemicals pan-caspase inhibitor q-vd-oph
Pan Caspase Inhibitor Q Vd Oph, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan-caspase inhibitor q-vd-oph/product/Selleck Chemicals
Average 90 stars, based on 1 article reviews
pan-caspase inhibitor q-vd-oph - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pan-caspase inhibitor z-vad-fmk  (Promega)
90
Promega pan-caspase inhibitor z-vad-fmk
A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) <t>Caspase</t> 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor <t>Z-VAD-FMK</t> (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.
Pan Caspase Inhibitor Z Vad Fmk, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan-caspase inhibitor z-vad-fmk/product/Promega
Average 90 stars, based on 1 article reviews
pan-caspase inhibitor z-vad-fmk - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pan caspase oph inhibitor q-vd, non-omethylated  (Bio-Techne corporation)
94
Bio-Techne corporation pan caspase oph inhibitor q-vd, non-omethylated
A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) <t>Caspase</t> 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor <t>Z-VAD-FMK</t> (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.
Pan Caspase Oph Inhibitor Q Vd, Non Omethylated, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase oph inhibitor q-vd, non-omethylated/product/Bio-Techne corporation
Average 94 stars, based on 1 article reviews
pan caspase oph inhibitor q-vd, non-omethylated - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
pan caspase inhibitor z vad fmk  (InvivoGen)
96
InvivoGen pan caspase inhibitor z vad fmk
A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) <t>Caspase</t> 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor <t>Z-VAD-FMK</t> (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.
Pan Caspase Inhibitor Z Vad Fmk, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor z vad fmk/product/InvivoGen
Average 96 stars, based on 1 article reviews
pan caspase inhibitor z vad fmk - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pan caspase inhibitor z vad fmk  (Selleck Chemicals)
96
Selleck Chemicals pan caspase inhibitor z vad fmk
A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) <t>Caspase</t> 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor <t>Z-VAD-FMK</t> (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.
Pan Caspase Inhibitor Z Vad Fmk, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor z vad fmk/product/Selleck Chemicals
Average 96 stars, based on 1 article reviews
pan caspase inhibitor z vad fmk - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
pan-caspase inhibitor z-vad-fmk  (MBL International)
90
MBL International pan-caspase inhibitor z-vad-fmk
A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) <t>Caspase</t> 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor <t>Z-VAD-FMK</t> (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.
Pan Caspase Inhibitor Z Vad Fmk, supplied by MBL International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan-caspase inhibitor z-vad-fmk/product/MBL International
Average 90 stars, based on 1 article reviews
pan-caspase inhibitor z-vad-fmk - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
benzyloxycarbonyl val ala asp fluoromethylketone  (R&D Systems)
95
R&D Systems benzyloxycarbonyl val ala asp fluoromethylketone
A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) <t>Caspase</t> 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor <t>Z-VAD-FMK</t> (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.
Benzyloxycarbonyl Val Ala Asp Fluoromethylketone, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/benzyloxycarbonyl val ala asp fluoromethylketone/product/R&D Systems
Average 95 stars, based on 1 article reviews
benzyloxycarbonyl val ala asp fluoromethylketone - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) Caspase 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor Z-VAD-FMK (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.

Journal: bioRxiv

Article Title: Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models

doi: 10.1101/2022.05.31.494146

Figure Lengend Snippet: A) Schematic illustrating PP2A reactivation predisposed to MKI-induced SL in GB. B) Representative images of colony formation assay in T98G cells under PME-1 deletion (siRNA or CRISPR/Cas9) or NZ-8-061 treatment. Cells were treated with 25 nM UCN-01 (UCN) or left untreated (NT). Immunoblot analysis of PME-1 (lower panel). C) Viability of T98G cells treated with increasing concentration of NZ-8-061 either alone or in combination with 25 nM UCN-01 (UCN) for 72 h. ***P<0.001, Student’s t -test. D) Synergy plot showing the most synergistic area (yellow box) between NZ-8-061 and UCN-01 in T98G cells. The Bliss synergy score is calculated over the whole dose-response matrix. E) Viability of T98G wt and SV40 small t-antigen-expressing (T98G-ST) cells treated with 25 nM UCN-01 (UCN) and 8 µM NZ-8-061, alone or in combination for 72 h. Immunoblot analysis of SV40 small t-antigen (right panel). **P<0.01, ***P<0.001 Student’s t -test. F) Caspase 3/7 activity in T98G cells treated with 8 µM NZ-8-061 alone or in combination with 25 nM UCN-01 (UCN) under caspase inhibitor Z-VAD-FMK (20 µM) for 24 h. ***P<0.001, Student’s t -test. G) Structures of two different classes of SMAPs. H) Viability of T98G cells treated SMAPs, 10 µM DBK-794 and 5 µM DBK-1154, alone or in combination with 25 nM UCN-01 (UCN) for 72 h. **P<0.01, ***P<0.001, Student’s t -test. I) Representative images (left) and quantified data of colony formation assay (right) in U251, U118, A172 and U87MG cells treated with 8 µM NZ-8-061 alone or in combination with UCN-01 (UCN; 200 nM, 25 nM, 50 nM and 500 nM, respectively). n=2 independent experiments, *P<0.05, **P<0.01, ***P<0.001, Student’s t -test.

Article Snippet: After 24 hours, cells were treated with the indicated drugs in combination with pan-caspase inhibitor Z-VAD-FMK (10 mM, Promega).

Techniques: Colony Assay, CRISPR, Western Blot, Concentration Assay, Expressing, Activity Assay